The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study.
Graham
S
S
Department of Urology of Emory University School of Medicine, Atlanta, GA.
Babayan
R K
RK
Lamm
D L
DL
Sawczuk
I
I
Ross
S D
SD
Lavin
P T
PT
Osband
M E
ME
Krane
R J
RJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D002927:Cimetidine / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007156:Immunologic Memory; D016219:Immunotherapy, Adoptive / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011446:Prospective Studies; D011788:Quality of Life; D012074:Remission Induction; D015996:Survival Rate; D013601:T-Lymphocytes; D014481:United States
D002927:Cimetidine